HJC0416

HJC0416 is a novel, potent, and orally active small molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). Developed by researchers at the University of Texas MD Anderson Cancer Center and the University of Texas Medical Branch, it was identified through fragment-based drug design to address the limitations of existing STAT3 inhibitors, such as poor solubility and bioavailability. HJC0416 functions by suppressing STAT3 promoter activity, inhibiting STAT3 phosphorylation at the Y705 site, and reducing total STAT3 protein levels. In preclinical studies, the compound has demonstrated the ability to induce cell growth arrest and apoptosis in ER-negative breast cancer (e.g., MDA-MB-231) and pancreatic cancer cell lines. Furthermore, it has shown efficacy in suppressing the growth of breast cancer xenograft tumors when administered via oral or intraperitoneal routes, exhibiting improved aqueous solubility and lower toxicity compared to earlier lead compounds.